Abstract Treatment options in multiple myeloma (MM) are increasing with the introduction of
complex multi-novel-agent-based regimens investigated in randomized clinical trials …

Bispecific antibodies targeting GPRC5D demonstrated promising efficacy in multiple
myeloma, but acquired resistance usually occurs within a few months. Using a single …

Although treatment of multiple myeloma (MM) with daratumumab significantly extends the
patient's lifespan, resistance to therapy is inevitable. ISB 1342 was designed to target MM …

To establish a strict p53-dependent gene-expression profile, TP53−/− clones were derived
from TP53+/+ and TP53−/mut t (4; 14) human myeloma cell lines (HMCLs) using …

Despite recent advances in immunotherapies targeting single tumor-associated antigens,
patients with multiple myeloma eventually relapse. ISB 2001 is a CD3+ T cell engager (TCE) …

Antibody engineering can tailor the design and activities of therapeutic antibodies for better
efficiency or other advantageous clinical properties. Here we report the development of ISB …

Secondary plasma cell leukemia (sPCL) is a rare form of aggressive plasma cell malignancy
arising mostly at end-stage refractory multiple myeloma and consequently presenting limited …

Objectives Mixing diagnostic and prognostic data provided by whole-body MRI (WB-MRI)
and 2-18F-fluorodeoxyglucose (2-[18F] FDG) positron emission tomography (2-[18F] FDG …

The therapeutic management of patients with multiple myeloma (MM) is complex. Despite
substantial advances, MM remains incurable, and management involves cycles of treatment …

Background: Bispecific antibodies (BsAb) are monoclonal antibodies that redirect T cells by
targeting both the T cell co-receptor CD3 and markers expressed on the surface of tumor …